Polaris Group

Polaris Group is a biopharmaceutical company dedicated to pioneering advanced therapies, primarily focusing on metabolic-related diseases. Our lead drug candidate, Pegargiminase (ADZODI), is presently advancing through the BLA-enabling stage for MPM and clinical development for other indications. Pegargiminase is a biologic in late-stage clinical development for a wide range of cancers, including hepatocellular carcinoma, soft tissue sarcoma, glioblastoma, non-small cell lung cancer, melanoma, acute myeloid leukemia and others. Pegargiminase is designed to disrupt cancer cell metabolism, providing a novel approach to treating a wide range of cancers heavily influenced by metabolic pathways. Our mission is to revolutionize the treatment of complex diseases like cancer by concentrating on their metabolic foundations, ultimately striving to enhance patient outcomes globally. For more information, please visit https://www.polarispharma.com.